gastroesophageal

PF 03716556 (PF-3716556) , an effective and specific P-CAB (potassium-competitive acid blocker), is utilized for the treatment of gastroesophageal reflux disease.

Ilaprazole (IY-81149) is a proton pump inhibitor used in the treatment of dyspepsia gastroesophageal reflux disease (GORD GERD) and duodenal ulcer. Studies also showed that Ilaprazole significantly prevented the development of reflux oesophagitis.

Nizatidine (Acinon) is a competitive and reversible histamine H2-receptor antagonist with antacid activity.

Vonoprazan Fumarate (TAK438) , a novel potassium-competitive acid blocker, inhibits gastric acid secretion. Vonoprazan Fumarate (TAK438) inhibited H+,K+-ATPase activity in porcine gastric microsomes with IC50 value of 19 nM at pH 6.5.

Esomeprazole Sodium ((S)-Omeprazole sodium) is the S-isomer of omeprazole with selective and irreversible proton pump inhibitor activity.Esomeprazole acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H+-ATPases

Esomeprazole Magnesium trihydrate ((S)-Omeprazole magnesium trihydrate) is a proton pump inhibitor indicated for the short-term treatment of gastroesophageal reflux disease in patients with a history of erosive esophagitis.Esomeprazole magnesium trihydrate acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H+-ATPases

Metoclopramide (5-Chloro-2-methoxyprocainamide) is a dopamine D2 antagonist which has been used for treatment of a variety of gastrointestinal symptoms over the last thirty years. In various countries, metoclopramide is the antiemetic drug of choice in pregnant women. Findings provide reassurance regarding the safety of metoclopramide for the fetus when the drug is given to women to relieve nausea and vomiting during pregnancy. Evidence also supports its use for gastroparesis (poor stomach emptying) and gastroesophageal reflux disease. It appears to bind to dopamine D2 receptors where it is a receptor antagonist, and is also a mixed 5-HT3 receptor antagonist 5-HT4 receptor agonist.

Pantoprazole Sodium Hydrate (BY1023 (sodium hydrate)) is a proton pump inhibitor drug, used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.

Esomeprazole is the S-isomer of omeprazole, inhibits the lysosomal cysteine protease legumain to prevent cancer metastasis. Esomeprazole is a proton pump inhibitors (PPI).

Pantoprazole (BY1023) is a proton pump inhibitor used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.

Ticalopride is a 5-HT3 receptor agonist used in the treatment of digestive disorders, orofacial disorders, otorhinolaryngologic disorders, and may be used in the study of bulimia nervosa, gastroesophageal reflux, and irritable bowel syndrome.

AZD 9272 is a brain-permeable mGluR5 antagonist for the study of gastroesophageal reflux.

Lansoprazole sodium (Lansoprazole (sodium)) is a proton pump inhibitor (PPI) and a potent inhibitor of gastric acidity which is widely used in the therapy of gastroesophageal reflux and peptic ulcer disease.

Abeprazan hydrochloride (Fexuprazan hydrochloride) is an effective reversible potassium-competitive acid blocker with oral activity, inhibiting H+, K+ -atPase by competitive binding to potassium ions without acid activation. Abeprazan hydrochloride is a proton pump inhibitor (PPI) that acts by reducing gastric acid production and is used to treat gastric acid-related disorders, such as gastroesophageal reflux disease (GERD) and peptic ulcers.

Nizatidine amide is a histamine H2 receptor antagonist that inhibits stomach acid production. It is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease.

Esomeprazole hemistrontium, also known as (S)-Omeprazole, is a potent and orally active proton pump inhibitor that effectively reduces acid secretion by inhibiting the H+, K+-ATPase in gastric parietal cells. This compound exhibits promising potential for research in symptomatic gastroesophageal reflux disease [1] [2] [3].

Osemitamab, an IgG1 antibody, targets human claudin-18.2 and comprises a human-Mus musculus monoclonal TST001 γ1-chain disulfide-bonded to a human-Mus musculus monoclonal TST001 κ-chain dimer (ACI). It is utilized, in conjunction with Capecitabine and Oxaliplatin, for gastric/gastroesophageal junction (G/GEJ) cancer studies [1] [2].

Retifanlimab, an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb), is utilized in the research of gastroesophageal adenocarcinoma (GEA) [1].

Azeloprazole, a proton pump inhibitor, is used potentially for the treatment of gastroesophageal reflux disease (GERD).

Itopride HCl is an AChE inhibitor and dopamine D2 receptor antagonist. It inhibits lower esophageal sphincter relaxation. It also used to treat functional dyspepsia and gastroesophageal reflux disease

Mitemcinal fumarate is a erythromycin derivative that is used to treat gastroesophageal reflux disease.

Famotidine propionic acid is a histamine H2-receptor antagonist that inhibits stomach acid production. It is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease.

Omeprazole acid is a medication used in the treatment of gastroesophageal reflux disease, peptic ulcer disease, and Zollinger–Ellison syndrome. It is also used to prevent upper gastrointestinal bleeding in people who are at high risk. Omeprazole is a proton pump inhibitor and as such blocks the release of stomach acid.

Cisapride tartrate is chemically related to metoclopramide, but unlike metoclopramide, it does not cross the blood-brain barrier or have antidopaminergic effects. Cisapride is a serotonin-4 (5-HT4) receptor agonist. Cisapride was indicated for the symptomatic treatment of adult patients with nocturnal heartburn due to gastroesophageal reflux disease. The Food and Drug Administration (FDA) in America stopped the marketing of cisapride as of 14th July 2000. They had received at least 341 reports of heart rhythm abnormalities and these led to 80 deaths. Other reported adverse effects are: headache, diarrhea, abdominal pain, nausea, constipation. Cisapride for animals has been found helpful in some cases of megaesophagus and is a common treatment for feline megacolon. Clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride. Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be e......

Vonoprazan hydrochloride, a proton pump inhibitor (PPI), effectively functions as a potassium-competitive acid blocker (P-CAB) with potent antisecretory properties. It significantly inhibits H+,K+-ATPase activity in porcine gastric microsomes, displaying an IC50 of 19 nM at pH 6.5. Developed primarily for researching acid-related conditions such as gastroesophageal reflux disease and peptic ulcer disease, vonoprazan hydrochloride also aids in the eradication of Helicobacter pylori [1] [2] [3].

Ranitidine-S-oxide is a metabolite of Ranitidine. It is commonly used in the treatment of peptic ulcer disease, Zollinger–Ellison syndrome，and gastroesophageal reflux disease.

Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is an effective and orally active proton pump inhibitor that inhibits H+, K+-ATPase enzyme in gastric parietal cells, reducing acid secretion. It is a promising compound for investigating symptomatic gastroesophageal reflux disease [1] [2] [3].

Famotine Hydrochloride is a histamine H2 receptor antagonist that suppresses acid production in the stomach and commonly treats peptic ulcer disease and gastroesophageal reflux disease.

Lafutidine (FRG-8813) is a newly developed histamine H2-receptor antagonist that inhibits gastric acid secretion.

Vonoprazan (TAK-438 (free base)) is an orally active potassium-competitive acid blocker.Vonoprazan can be used for the treatment of gastroduodenal ulcer and reflux esophagitis

Famotine is a histamine H2 receptor antagonist that inhibits stomach acid production. It is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease.

Famotidine disulfide is a histamine H2-receptor antagonist that inhibits stomach acid production. It is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease.

Pantoprazole-d6 is a deuterated compound of Pantoprazole. Pantoprazole has a CAS number of 102625-70-7. Pantoprazole is a proton pump inhibitor used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.

Rabeprazole sodium (Habeprazole Sodium) is a 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of stomach ulcers and Zollinger-Ellison syndrome. The drug inhibits H(+)-K(+)-exchanging ATPase which is found in gastric parietal cells.

Arbaclofen placarbil( XP19986) is a GABA(B) receptor agonist.Arbaclofen Placarbil is a novel R-baclofen prodrug with improved absorption, distribution, metabolism, and elimination properties compared to R-baclofen. And it can reduce postprandial reflux in

Famotidine propanamide is a histamine H2-receptor antagonist that inhibits stomach acid production. It is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease.

Esomeprazole magnesium salt is a potent and orally active proton pump inhibitor that effectively reduces acid secretion in gastric parietal cells by inhibiting the H+, K+-ATPase. This compound has shown promise for the research and treatment of symptomatic gastroesophageal reflux disease [1][2][3].

Pumosetrag Hydrochloride is an orally available 5-HT3 partial agonist. It is developed for the treatment of irritable bowel syndrome and gastroesophageal reflux disease.

Revexepride is a highly selective agonist of the 5-HT4 receptor and a potential inducer of CYP3A4 enzyme. Revexepride is used for the treatment of gastroesophageal reflux disease.

Famotidine sulfamoyl propanamide is a histamine H2-receptor antagonist that inhibits stomach acid production. It is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease.

Levolansoprazole ((S)-Lansoprazole), a proton pump inhibitor, irreversibly inhibits H+ K+-stimulated ATPase pumps in parietal cells (IC50: 5.2 μM). It also inhibits acid formation in isolated canine parietal cells (IC50: 82 μM). Both (R)- and (S)-lansoprazole are pharmacologically active with similar potencies.

Lansoprazole D4 (AG-1749 D4) is a deuterium labeled Lansoprazole. Lansoprazole is an inhibitor of proton pump which prevents the stomach from producing acid.

Lansoprazole (A-65006) is a 2, 2, 2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)

(R)-Lansoprazole (T 168390) is the R-isomer of lansoprazole and a substituted benzimidazole prodrug with selective and irreversible proton pump inhibitor activity.Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)

Pantoprazole sulfide is a metabolite of the gastric H+/K+ ATPase pump inhibitor pantoprazole . Pantoprazole is metabolized by the cytochrome P450 (CYP) isomers CYP2C19 and CYP3A4 to form pantoprazole sulfide.

Pantoprazole sodium (Pantecta) is the sodium salt form of a substituted benzimidazole with proton pump inhibitor activity. Pantoprazole sodium is a lipophilic, weak base that crosses the parietal cell membrane and enters the acidic parietal cell canaliculus where it becomes protonated, producing the active metabolite sulfenamide, which forms an irreversible covalent bond with two sites of the H+ K+-ATPase enzyme located on the gastric parietal cell, thereby inhibiting both basal and stimulated gastric acid production.